BMNR: A Tale of Staking, Sarcasm, and $300 Million Whispers
MAVAN, born on March 25, cradles 3,142,643 ETH, a treasure valued at $6.8 billion. At a yield of 2.83%, it whispers promises of $300 million in annual staking rewards. A built-in yield engine, it hums, indifferent to the capricious whims of price, fueled instead by the steady pulse of deployed capital.




![This research demonstrates a selective cost reduction and error control mechanism-SCoRE-that optimizes predictions in both drug discovery and clinical applications; in drug discovery, SCoRE minimizes average cost [latex]L\_{n+1}\operatorname{\mathds{1}}\{Y\_{n+1}\leq c\}[/latex] among selected compounds while maintaining activity below a threshold of [latex]\alpha=1[/latex], and in clinical prediction, it identifies health outcome predictions with minimal error [latex]f(X\_{n+1})\approx Y\_{n+1}[/latex] and controls total squared error during deployment, as validated through simulations on a semi-synthetic dataset.](https://arxiv.org/html/2603.24704v1/x1.png)



